Panbela regains worldwide rights to develop and commercialize flynpovitm in patients with familial adenomatous polyposis (fap)

Minneapolis, april 11, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs today announced that it has regained the north american rights to develop and commercialize flynpovi (the combination of cpp-1x (eflornithine) and sulindac) in patients with familial adenomatous polyposis (fap), as a result of the termination of the licensing agreement between cancer prevention pharmaceuticals, inc. (cpp) and with one-two therapeutics assets limited.
PBLA Ratings Summary
PBLA Quant Ranking